IDEXX Laboratories Inc (BSP:I1DX34)
R$ 485.25 0 (0%) Market Cap: 200.38 Bil Enterprise Value: 203.84 Bil PE Ratio: 48.70 PB Ratio: 26.57 GF Score: 99/100

IDEXX Laboratories Inc at Raymond James Institutional Investors Conference Transcript

Mar 02, 2020 / 03:25PM GMT
Andrew Harris Cooper
Raymond James & Associates, Inc., Research Division - Senior Research Associate

Good morning. I'm Andrew Cooper, part of the animal health research team here at Raymond James. I'm going to be quick here because I've been told that Jay's presentation is 29 minutes and 45 seconds. But we're excited to have IDEXX here, leading player in animal health diagnostics markets, fast-growing market and a business that's really been able to outpace that market and drive a lot of the, frankly, market growth as well with nice margin expansion as well and a 15% to 20% EPS growth goal long term that trying to think any time there's been a slip on that and can't come up with one.

So with that, I'll leave it to Jay.

Jonathan J. Mazelsky
IDEXX Laboratories, Inc. - President, CEO & Director

Thank you, Andrew, and good morning. I'd like to welcome everybody to a strategic overview of IDEXX. I'm Jay Mazelsky, I'm CEO of IDEXX. I'd like to welcome everybody here in the room as well as those participating in the webcast.

I'd also like

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot